Kymera Therapeutics Inc Cash Flow Conversion Efficiency
Kymera Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has a cash flow conversion efficiency ratio of -0.036x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.06 Million) by net assets ($1.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kymera Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2025. This chart illustrates how Kymera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kymera Therapeutics Inc stock quote for real-time trading data and today's change.
Kymera Therapeutics Inc Cash Flow Conversion Ratio Explained
Kymera Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kymera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kymera Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Kymera Therapeutics Inc (KYMR) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Storebrand ASA
OL:STB
|
0.363x |
|
Equinox Gold Corp
TO:EQX
|
0.035x |
|
Baloise Holding AG
SW:BALN
|
0.211x |
|
Core & Main Inc
NYSE:CNM
|
0.039x |
|
Aptiv PLC
NYSE:APTV
|
0.011x |
|
Embraer S.A
F:EMY
|
0.225x |
|
CareTrust REIT Inc.
NYSE:CTRE
|
0.022x |
|
Autoliv Inc
NYSE:ALV
|
0.174x |
Annual Cash Flow Conversion Efficiency for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2025. Review KYMR cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.58 Billion | $-232.89 Million | -0.147x | +36.66% |
| 2024-12-31 | $835.62 Million | $-194.50 Million | -0.233x | +10.59% |
| 2023-12-31 | $394.97 Million | $-102.83 Million | -0.260x | +16.64% |
| 2022-12-31 | $490.15 Million | $-153.09 Million | -0.312x | -11.33% |
| 2021-12-31 | $459.64 Million | $-128.95 Million | -0.281x | -190.37% |
| 2020-12-31 | $283.89 Million | $88.13 Million | 0.310x | +229.01% |
| 2019-12-31 | $-74.41 Million | $17.91 Million | -0.241x | -146.39% |
| 2018-12-31 | $-34.44 Million | $-17.86 Million | 0.519x | -- |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more